Zydus announces Phase IV trial of Desidustat

Insight Online News

Mumbai, Aug 30 : Zydus Lifesciences , a discovery-driven, global life sciences company, announced the commencement of Phase IV clinical trial for Desidustat in patients with Chronic Kidney Disease (CKD) induced anemia.

CKD is predicted to become one of the most common causes of premature death by 2040 globally. It is estimated that 115.1 million people in India, 132 million in China, 38 million in the United States, 21 million in Japan and 41 million people in Western Europe are living with CKD.

The Phase IV DREAM-CKD trial will enroll 1,004 CKD patients in India, including 502 dialysis dependent and 502 dialysis independent CKD patients with anemia.

Dr. Ajay K. Singh, a senior nephrologist at the Brigham and Women’s Hospital and Harvard Medical School, said: “This Phase 4 DREAM-CKD study will help generate Real World Data (RWD) in CKD patients and will add to our existing knowledge of Desidustat. Real World Data is crucial to understanding how Desidustat works in diverse settings and will be critical to generate real world evidence which will help formulate clinical guidelines, to further support its use in clinical practice.”

Pankaj R. Patel, Chairman, Zydus Lifesciences Ltd, said: “Desidustat testifies our commitment to innovation.It exemplifies our endeavour to develop novel best-in-class innovative medicines, which is backed by robust clinical trial results and publications in peer-reviewed scientific journals. This novel medicine will meet the needs of millions of patients living with Chronic Kidney Disease induced anemia.”


Leave a Reply

Your email address will not be published. Required fields are marked *